Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer

Cambridge, UK, 14 June 2022: Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of superior and differentiated ADCs in the treatment of solid tumours where there is a high unmet need.
More info >>